Welcome to our dedicated page for GSK plc SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reports that, acting through BNP Paribas, it repurchased 430,000 ordinary shares on 27 February 2026 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,153.00p and 2,197.00p per share, at a volume‑weighted average price of 2,179.36p.
The purchased shares will be held as treasury shares. Since 17 February 2026, the company has bought back a total of 4,136,000 ordinary shares. Following this latest transaction, GSK holds 244,027,094 shares in treasury and has 4,072,135,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares now represent 5.99% of voting rights.
GSK plc reports its share capital and voting rights position as of 28 February 2026. The company had 4,316,162,488 issued ordinary shares of 31 ¼ pence each, with 244,027,094 of these held in treasury. Shares held in treasury do not carry voting rights.
After excluding treasury shares, the total number of voting rights in GSK is 4,072,135,394. Shareholders can use this figure as the denominator when calculating whether they must notify the company and the UK regulator of any interests or changes in their holdings.
GSK plc reports that executive Maya Martinez-Davis acquired 70.566 American Depositary Shares at $59.5200 each on 2026-02-20 through dividend reinvestment in her GSK Executive Supplemental Savings Plan account. The transaction took place on the New York Stock Exchange and was disclosed as an initial notification.
GSK plc reports that, on 26 February 2026, it bought 545,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme, at a volume‑weighted average price of 2,186.88p per share.
The shares will be held as treasury shares. After this transaction, GSK holds 243,597,094 shares in treasury and has 4,072,555,332 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 5.98% of voting rights.
GSK reports that China’s National Medical Products Administration has accepted its new drug application for linerixibat for priority review to treat cholestatic pruritus in adults with primary biliary cholangitis, a rare autoimmune liver disease.
The submission is based on the positive phase III GLISTEN trial, where linerixibat showed rapid, significant and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo, with a safety profile consistent with earlier studies and its IBAT-inhibitor mechanism. In China, primary biliary cholangitis affects about 280,000 people, and cholestatic pruritus can impact up to 89% of patients over the course of their disease, with few effective treatment options. Linerixibat has Orphan Drug Designation in the US, EU and Japan, and marketing applications are under review in the US, EU, UK and Canada, but it is not yet approved anywhere.
GSK reports that Japan's Ministry of Health, Labour and Welfare has accepted for review a new drug application for bepirovirsen as a treatment for adults with chronic hepatitis B. This is the first regulatory filing globally for the drug and follows positive phase III B-Well trial results showing statistically significant and clinically meaningful functional cure rates when added to standard therapy.
Bepirovirsen, an investigational antisense oligonucleotide, targets hepatitis B viral RNA to reduce viral replication and surface antigen levels, while stimulating the immune system. It has SENKU designation in Japan, which enables expedited review, and has also received Fast Track or similar designations in other major markets, but it is not yet approved anywhere.
GSK plc reports that on 25 February 2026 it repurchased 455,000 ordinary shares of 31¼ pence each through BNP Paribas at a volume-weighted average price of 2,209.58p, with prices ranging from 2,176.00p to 2,217.00p per share.
The shares will be held as treasury shares as part of its existing buyback programme started under a non-discretionary agreement on 17 February 2026, since when 3,161,000 shares have been bought. After this transaction, GSK holds 243,052,094 shares in treasury and has 4,073,100,332 shares in issue and voting rights, with treasury shares representing 5.97% of voting rights.
GSK plc reported that Chief People Officer Diana Conrad acquired American Depositary Shares through a company pension plan. The transaction involved the purchase of 11.163 ADS at a price of CAD 82.8205 per ADS on 2026-02-13 on the New York Stock Exchange.
GSK plc reported that non-executive director Dr Hal Barron acquired additional American Depositary Shares through his GSK 401(k) plan. The purchase resulted from the reinvestment of dividends, leading to the acquisition of 64 ADS at a price of $59.5200 per ADS.
The transaction took place on 2026-02-20 on the New York Stock Exchange (XNYS). This reflects automatic plan-based dividend reinvestment rather than an open‑market discretionary trade.
GSK plc has agreed to acquire Canada-based 35Pharma Inc., a private clinical-stage biopharma company, for $950 million in cash at closing. The deal adds HS235, a potential best-in-class activin signalling inhibitor for cardiopulmonary diseases, to GSK’s pipeline.
HS235 has completed phase I trials in healthy volunteers, with studies starting in pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction. GSK highlights HS235’s design to lower bleeding risk and its potential metabolic benefits, aiming to strengthen its Respiratory, Immunology and Inflammation portfolio in a pulmonary hypertension market forecast to reach $18 billion by 2032.